GoodRx Holdings (GDRX) Current Deferred Revenue (2019 - 2023)

GoodRx Holdings (GDRX) has 5 years of Current Deferred Revenue data on file, last reported at $10.8 million in Q1 2023.

• For the quarter ending Q1 2023, Current Deferred Revenue rose 4.3% year-over-year to $10.8 million; the trailing twelve-month figure through Mar 2023 stood at $10.8 million (up 4.3% YoY), and the FY2022 full-year result was $7.9 million, up 15.01% from the prior year.
• Current Deferred Revenue climbed to $10.8 million in Q1 2023, from $7.9 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $11.5 million in Q2 2022 to a low of $3.5 million in Q4 2019.
• A 5-year average of $8.5 million and a median of $8.5 million in 2021 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue jumped 98.44% in 2020 and rose 0.25% in 2021, its largest moves.
• Tracing GDRX's Current Deferred Revenue over 5 years: stood at $3.5 million in 2019, then jumped by 98.44% to $6.9 million in 2020, then rose by 0.25% to $6.9 million in 2021, then climbed by 15.01% to $7.9 million in 2022, then jumped by 36.24% to $10.8 million in 2023.
• Business Quant data shows GDRX's Current Deferred Revenue at $10.8 million in Q1 2023, $7.9 million in Q4 2022, and $11.0 million in Q3 2022.